What is the newest evidence about PCSK9 inhibitors? (Medscape AI)

Recent studies have extended insights into both the safety profile and broader cardiovascular benefits of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition beyond traditional LDL-C lowering. https://www.medscape.com/ai-search?query=What%20is%20the%20newest%20evidence%20about%20PCSK9%20inhibitors%3F%20&ecd=wnl_tp10_daily_251231_MSCPEDIT_etid7997823&uac=148436CN&impID=7997823